Your browser doesn't support javascript.
loading
Application of Multi-Criteria Decision Analysis (MCDA) to Prioritize Real-World Evidence Studies for Health Technology Management: Outcomes and Lessons Learned by the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration.
Takhar, Pam; Geirnaert, Marc; Gavura, Scott; Beca, Jaclyn; Mercer, Rebecca E; Denburg, Avram; Muñoz, Caroline; Tadrous, Mina; Parmar, Ambica; Dionne, Francois; Boehm, Darryl; Chambers, Carole; Craig, Erica; Trudeau, Maureen; Cheung, Matthew C; Houlihan, Joanne; McDonald, Valerie; Pechlivanoglou, Petros; Taylor, Marianne; Wasylenko, Eric; Wranik, Wieslawa Dominika; Chan, Kelvin K W.
Afiliación
  • Takhar P; Ontario Health (Cancer Care Ontario), Toronto, ON M5G 2L3, Canada.
  • Geirnaert M; CancerCare Manitoba, Winnipeg, MB R3E 0V9, Canada.
  • Gavura S; Ontario Health (Cancer Care Ontario), Toronto, ON M5G 2L3, Canada.
  • Beca J; Ontario Health (Cancer Care Ontario), Toronto, ON M5G 2L3, Canada.
  • Mercer RE; Canadian Centre for Applied Research in Cancer Control, Toronto, ON M5G 2L3, Canada.
  • Denburg A; Ontario Health (Cancer Care Ontario), Toronto, ON M5G 2L3, Canada.
  • Muñoz C; Canadian Centre for Applied Research in Cancer Control, Toronto, ON M5G 2L3, Canada.
  • Tadrous M; Evaluative Clinical Services, Sunnybrook Research Institute, Toronto, ON M4N 3M3, Canada.
  • Parmar A; Division of Haematology/Oncology, The Hospital for Sick Children, Toronto, ON M5G 1X8, Canada.
  • Dionne F; Ontario Health (Cancer Care Ontario), Toronto, ON M5G 2L3, Canada.
  • Boehm D; Canadian Centre for Applied Research in Cancer Control, Toronto, ON M5G 2L3, Canada.
  • Chambers C; Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON M5S 3M2, Canada.
  • Craig E; Women's College Hospital, Toronto, ON M5S 1B2, Canada.
  • Trudeau M; Division of Medical Oncology & Hematology, Department of Medicine, Sunnybrook Health Sciences Centre, Toronto, ON M4N 3M3, Canada.
  • Cheung MC; Temerty Faculty of Medicine, University of Toronto, Toronto, ON M5S 1A8, Canada.
  • Houlihan J; Prioritize Consulting Ltd., Vancouver, BC V6S 2B3, Canada.
  • McDonald V; Saskatchewan Cancer Agency, Regina, SK S4W 0G3, Canada.
  • Pechlivanoglou P; Alberta Health Services, Calgary, AB T5J 3E4, Canada.
  • Taylor M; New Brunswick Cancer Network, Fredericton, NB E3B 5G8, Canada.
  • Wasylenko E; Division of Medical Oncology & Hematology, Department of Medicine, Sunnybrook Health Sciences Centre, Toronto, ON M4N 3M3, Canada.
  • Wranik WD; Evaluative Clinical Services, Sunnybrook Research Institute, Toronto, ON M4N 3M3, Canada.
  • Chan KKW; Division of Medical Oncology & Hematology, Department of Medicine, Sunnybrook Health Sciences Centre, Toronto, ON M4N 3M3, Canada.
Curr Oncol ; 31(4): 1876-1898, 2024 04 01.
Article en En | MEDLINE | ID: mdl-38668044
ABSTRACT
Multi-criteria decision analysis (MCDA) is a value assessment tool designed to help support complex decision-making by incorporating multiple factors and perspectives in a transparent, structured approach. We developed an MCDA rating tool, consisting of seven criteria evaluating the importance and feasibility of conducting potential real-world evidence (RWE) studies aimed at addressing uncertainties stemming from initial cancer drug funding recommendations. In collaboration with the Canadian Agency for Drugs and Technologies in Health's Provincial Advisory Group, a validation exercise was conducted to further evaluate the application of the rating tool using RWE proposals varying in complexity. Through this exercise, we aimed to gain insight into consensus building and deliberation processes and to identify efficiencies in the application of the rating tool. An experienced facilitator led a multidisciplinary committee, consisting of 11 Canadian experts, through consensus building, deliberation, and prioritization. A total of nine RWE proposals were evaluated and prioritized as low (n = 4), medium (n = 3), or high (n = 2) priority. Through an iterative process, efficiencies and recommendations to improve the rating tool and associated procedures were identified. The refined MCDA rating tool can help decision-makers prioritize important and feasible RWE studies for research and can enable the use of RWE for the life-cycle evaluation of cancer drugs.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Técnicas de Apoyo para la Decisión / Antineoplásicos Límite: Humans País/Región como asunto: America do norte Idioma: En Revista: Curr Oncol Año: 2024 Tipo del documento: Article País de afiliación: Canadá Pais de publicación: Suiza
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Técnicas de Apoyo para la Decisión / Antineoplásicos Límite: Humans País/Región como asunto: America do norte Idioma: En Revista: Curr Oncol Año: 2024 Tipo del documento: Article País de afiliación: Canadá Pais de publicación: Suiza